News for 'us-fda'

Ranbaxy discontinues arthritis drug

Ranbaxy discontinues arthritis drug

Rediff.com12 Apr 2005

Ranbaxy Laboratories Ltd on Tuesday said it has decided to discontinue all its 'Valdecoxib' formulations with immediate effect from Indian markets.

Indian drug cos to benefit as US expedites generic clearances

Indian drug cos to benefit as US expedites generic clearances

Rediff.com12 May 2014

Even smaller companies like Torrent Pharma and Alembic file five to 10 ANDAs every year.

Ranbaxy shares jump on drug approval in US

Ranbaxy shares jump on drug approval in US

Rediff.com27 Jun 2014

Earlier in April, Sun Pharmaceuticals Industries announced acquisition of Ranbaxy in an all-share deal.

Cadila gets USFDA nod for Gatifloxacin

Cadila gets USFDA nod for Gatifloxacin

Rediff.com29 Nov 2005

Cadila Healthcare Ltd has received tentative approval from US FDA to market its antibiotic, Gatifloxacin tablets, 200 mg and 400 mg, in the US market.

Cadila gets USFDA approval for Levofloxacin

Cadila gets USFDA approval for Levofloxacin

Rediff.com24 Apr 2006

Cadila Healthcare Ltd on Monday said it has received tentative approval from the US FDA to market Levofloxacin tablets of 250 mg, 500 mg and 750 mg in the US market.

Ind-Swift's $15 m GDR by June-end

Ind-Swift's $15 m GDR by June-end

Rediff.com10 Jun 2005

Sun-Ranbaxy merger may spill over to 2015

Sun-Ranbaxy merger may spill over to 2015

Rediff.com15 Nov 2014

The Competition Commission of India and the US Federal Trade Commission are yet to give their nod to the biggest pharma merger and acquisition deal this year in the Asia-Pacific region.

Oral insulin: Biocon seeks FDA nod

Oral insulin: Biocon seeks FDA nod

Rediff.com20 Apr 2005

Biotech major Biocon will file an application with the US Federal Drug Administration to begin clinical trials for oral insulin, which, it says, would be the world's first insulin that could be consumed orally.

Sandoz opens third plant in India

Sandoz opens third plant in India

Rediff.com19 May 2004

Global generic drugs producer Sandoz has opened its third plant in India at Navi Mumbai with annual production capacity of one billion tablets and capsules.

David vs Goliath: How Wockhardt plans to beat global challenge

David vs Goliath: How Wockhardt plans to beat global challenge

Rediff.com22 Jan 2018

Only 11 antibiotics in clinical trials have received qualified infectious disease product status from the US FDA, of which five are Wockhardt's drugs.

GSK withdraws sale of Zinetac after health alert

GSK withdraws sale of Zinetac after health alert

Rediff.com26 Sep 2019

GSK is continuing with investigations into the potential source of the NDMA, which is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.

Indian pharma exports report double-digit growth after 3 yrs

Indian pharma exports report double-digit growth after 3 yrs

Rediff.com3 May 2019

The only category of pharmaceuticals that showed a negative growth in exports this time was herbal products, exports of which stood at $299 million as compared to $ 312 million in the previous year.

Don't need to sell assets, can pay fine: Ranbaxy brothers

Don't need to sell assets, can pay fine: Ranbaxy brothers

Rediff.com25 May 2016

In 2013, Daiichi had launched the arbitration proceedings in Singapore.

Covid-19 could be the boost Indian pharma cos need

Covid-19 could be the boost Indian pharma cos need

Rediff.com20 Sep 2020

The western world had largely considered India to be a production hub, and also, a good potential geography for clinical trials, and a big market. But in Covid-19 research, Indian companies and government researchers are also researching new drug candidates and potential vaccines, says Prosenjit Datta.

Dr Reddy's Labs in steady mode

Dr Reddy's Labs in steady mode

Rediff.com26 Mar 2003

Dr Reddy's shrugged off recent volatility on Wednesday and moved tenaciously on filing new gernerics with the US FDA.

Glenmark gets USFDA nod for drug

Glenmark gets USFDA nod for drug

Rediff.com19 Jun 2013

Riluzole is indicated for the treatment of amyotrophic lateral sclerosis.

India's Super Rich got richer in 2017

India's Super Rich got richer in 2017

Rediff.com8 Jan 2018

Of the 23 Indian billionaires mentioned in the Bloomberg Billionaires Index, only one saw a reduction in net worth, with the companies owned by most of them outperforming the Nifty 50 index by a big margin.

Why 1,700 employees of Pfizer's India arm may lose their jobs

Why 1,700 employees of Pfizer's India arm may lose their jobs

Rediff.com10 Jan 2019

A key lesson for the pharmaceutical sector in this case is to not downplay the significant impact that regulatory non-compliance can have on operations.

Markets end flat on caution ahead of Fed, RBI meet

Markets end flat on caution ahead of Fed, RBI meet

Rediff.com16 Sep 2013

The broader markets ended negatively with mid-caps and small-caps shedding 0.5 per cent on the BSE.

COVID-19 doubling rate improves to 7.5 days: Centre

COVID-19 doubling rate improves to 7.5 days: Centre

Rediff.com20 Apr 2020

In its daily briefing, the government also reported Goa is now free of coronavirus.

Ranbaxy drugs cleared FDA test before import alert

Ranbaxy drugs cleared FDA test before import alert

Rediff.com11 Jun 2013

FDA had also issued warning letters to Ranbaxy's Paonta Sahib and Dewas facilities as it found extensive problems and deviations from manufacturing norms.

Company Watch: Emami, Shriram Transport, Lupin

Company Watch: Emami, Shriram Transport, Lupin

Rediff.com8 Feb 2021

Check out some of the stocks that will react on the basis of their numbers in the near term.

10 large caps for good returns in 2021

10 large caps for good returns in 2021

Rediff.com15 Jan 2021

Investment in market leaders with a safety-first approach could yield reasonable returns across sectors.

Sensex up over 200 points on global cues; Nifty hits 8,500

Sensex up over 200 points on global cues; Nifty hits 8,500

Rediff.com7 Nov 2016

Lupin was the top gainer after the USFDA cleared its Goa facility

Covid-19: How the testing infrastructure is struggling

Covid-19: How the testing infrastructure is struggling

Rediff.com25 Mar 2020

'India is too large a place to have just 10 labs performing these Covid-19 tests.'

Metal, healthcare, pharma power Sensex by 244 pts

Metal, healthcare, pharma power Sensex by 244 pts

Rediff.com19 Jul 2017

The 50-share NSE Nifty stayed in the positive zone and retook the 9,900-mark to hit a high of 9,905.05 as buying paced up towards the fag end. It settled higher by 72.45 points, or 0.74 per cent, at 9,899.60.

US regulator fast-tracks approval for Wockhardt drugs

US regulator fast-tracks approval for Wockhardt drugs

Rediff.com1 Sep 2014

These drugs will be entering in their global Phase -3 clinical trials early next year.

Lupin acquires US generics firm GAVIS for $880 mn

Lupin acquires US generics firm GAVIS for $880 mn

Rediff.com24 Jul 2015

Lupin will fund the buy through $100 mn cash reserves and a bridge loan.

In a first, a robot will perform angioplasty in Ahmedabad hospital

In a first, a robot will perform angioplasty in Ahmedabad hospital

Rediff.com5 Jan 2018

The procedure, however, would cost around Rs 75,000-100,000 more than conventional angioplasty.

Markets consolidate gains in choppy trade

Markets consolidate gains in choppy trade

Rediff.com6 Apr 2018

In the Sensex pack, ICICI Bank emerged as the top gainer by rising 0.97 per cent, while Tata Steel advanced 0.92 per cent.

Aurobindo Pharma embroiled in patent cases in the US

Aurobindo Pharma embroiled in patent cases in the US

Rediff.com28 Apr 2014

According to the petition copies, Hospira has alleged that Aurobindo's Abbreviated New Drug Application (ANDA) to make generic version of dexmedetomidine hydrochloride injection would infringe its patented drug Precedex.

Religare's banking bid under Ranbaxy cloud

Religare's banking bid under Ranbaxy cloud

Rediff.com1 Jun 2013

Singh brothers might be stopped by 'fit & proper' hurdle due to US drug norm violations; firm says confident of qualifying.

'Why did the government delay the vaccine?'

'Why did the government delay the vaccine?'

Rediff.com14 Apr 2021

'The government had a vaccine from January.' 'The government should have given the vaccine to all population above the age of 45, right from the start.' 'Each state has its own problems, but as far as vaccine coverage in India is concerned, there have been mistakes.'

Nestle India did not opt for re-test, instead burnt Maggi: FDA

Nestle India did not opt for re-test, instead burnt Maggi: FDA

Rediff.com29 Jul 2015

Maharashtra's Food and Drugs Administration on Wednesday argued in the Bombay High Court that Nestle India.